drugset / Trial / NCT06915233

A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle

NCT06915233 ↗

Phase 3 Recruiting 309 enrolled Vericel Corporation
RandomizedParallel-groupOpen-labelTreatment

Summary

The objective of this study is to demonstrate the superiority of MACI (autologous cultured chondrocytes on porcine collagen membrane) versus Bone Marrow Stimulation in the treatment of patients aged 17 to 65 years with symptomatic articular chondral or osteochondral defects of the talus.

Timeline

Start
2026-05
Primary completion
2030-07
Completion
2030-07

Drugs

EvaluationDrugModalityDoseRoute
Subject MACI Cell therapy — Other

Indications